Febuxostat for treatment of chronic gout

American Journal of Health-System Pharmacy

Volumn 68, Issue 5, 2011, Pages 389-398

  Gray, Charnelda L ^a   Walters Smith, Nafesa E ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

Dosage; Enzyme inhibitors; Febuxostat; Gout; Mechanism of action; Pharmacokinetics; Toxicity

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; PLACEBO; URIC ACID;

ABDOMINAL PAIN; ARTHRALGIA; CHRONIC DISEASE; CLINICAL TRIAL; CONGENITAL MALFORMATION; DIZZINESS; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GERIATRICS; GOUT; HEADACHE; HEART INFARCTION; HUMAN; HYPERURICEMIA; KIDNEY DISEASE; LIVER DISEASE; LIVER FUNCTION TEST; LONG TERM CARE; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TREATMENT DURATION; URIC ACID BLOOD LEVEL;

EID: 79956058299     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100394     Document Type: Review

References (42)

1. Takano Y, Hase-Aoki K, Horiuchi H et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005; 76:1835-47. (Pubitemid 40215224)
2. Febuxostat (Uloric) for chronic treatment of gout. Med Lett Drugs Ther. 2009; 51:37-8.
3. Becker MA, Kisicki J, Khosravan R et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in health volunteers. Nucleosides Nucleotides Nucleic Acids. 2004; 23:1111-6. (Pubitemid 39625877)
4. Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res. 2006; 8(suppl 1):S1.
5. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005; 143:499-516. (Pubitemid 41379398)
6. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis. 2002; 40:37-42.
7. Adams PF, Henderson GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. www.cdc.gov/nchs/data/series/sr-10/sr10-200.pdf (accessed 2010 Oct 13).
8. Colwell HH, Hut BJ, Pasta DJ et al. Gout assessment questionnaire: initial results of reliability, validity and responsiveness. Int J Clin Pract. 2006; 60:1210-7. (Pubitemid 44375441)
9. Lawrence RC, Felson DT, Helmick CG. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum. 2008; 58:26-35.
10. Becker MA, Schumacher HR Jr, Wortmann RL et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: a twenty-eight day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005; 52:916-23. (Pubitemid 40372228)
11. Becker MA, Schumacher HR, MacDonald PA et al. Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009; 36:1273-82.
12. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987; 82:421-6.
13. Wallace SL, Robinson H, Masi AT. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977; 20:895-900.
14. Khosravan R, Kukulka MJ, Wu JT et al. The effect of age and gender on pharmacokinetics, pharmacodynamics and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2008; 48:1014-24.
15. Schlesinger N, Dalbeth N, Perez-Ruiz F. Gout - what are the treatment options? Expert Opin Pharmacother. 2009; 10:1319-28.
16. Schlesinger N. Diagnosis of gout: clinical, laboratory and radiologic findings. Am J Manag Care. 2005; 11(suppl):S443-50.
17. Falasca GF. Metabolic diseases: gout. Clin Dermatol. 2006; 24:498-508. (Pubitemid 44750555)
18. Schumacher HR, Chen L. Newer therapeutic approaches: gout. Rheum Dis Clin North Am. 2006; 32:235-44. (Pubitemid 43292534)
19. Kamper AL, Nielsen AH. Uricosuric effect of losartan in patients with renal transplants. Transplantation. 2001; 72:671-4. (Pubitemid 32802751)
20. Feher MD, Hepburn AL, Hogarth MB et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricemia and gout. Rheumatology. 2003; 42:321-5. (Pubitemid 36305620)
21. Stein HB, Hassan A, Fox IH. Ascorbic acid-induced uricosuria. A consequence of megavitamin therapy. Ann Intern Med. 1976; 84:385-8.
22. Emmerson BT. The management of gout. N Engl J Med. 1996; 334:445-51. (Pubitemid 126528536)
23. Stamp LK, O'Donnell JL, Chapman PT. Emerging therapies in long-term management of hyperuricaemia and gout. Int Med J. 2007; 37:258-66. (Pubitemid 46457505)
24. Komoriya K, Hohise S, Takeda K et al. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia. Nucleosides Nucleotides Nucleic Acids. 2004; 23:1119-22. (Pubitemid 39625879)
25. Osada Y, Tsuchimoto M, Fukushima H et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol. 1993; 241:183-8. (Pubitemid 23272878)
26. Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother. 2006; 40:2187-94. (Pubitemid 44954438)
27. Schumacher HR. Febuxostat: a nonpurine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. Expert Opin Investig Drugs. 2005; 14:893-903.
28. Mukoyoshi M, Nishimura S, Hoshide S et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica. 2008; 38:496-510. (Pubitemid 351550978)
29. Khosravan R, Grabowski BA, Wu JT. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet. 2006; 45:821-41. (Pubitemid 44192308)
30. Uloric (febuxostat) prescribing information. Deerfield, IL: Takeda Pharmaceuticals North America; 2009.
31. Mayer MD, Khosravan R, Vernillet L. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005; 12:22-34. (Pubitemid 40516043)
32. Khosravan R, Grabowski BA, Mayer MD et al. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2006; 46:88-102. (Pubitemid 43021717)
33. Khosravan R, Erdman K, Vernillet L et al. Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate in healthy subjects. Clin Pharmacol Ther. 2005; 77:P43. Abstract.
34. Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65:1312-24. (Pubitemid 44620440)
35. Becker MA, Schumacher HR, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353:2450-61. (Pubitemid 41781828)
36. Lustberg ME. Febuxostat versus allopurinol for gout. N Engl J Med. 354; 14:1532-3. Letter.
37. Schumacher HR, Becker MA, Wortmann RL et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59:1540-8.
38. Becker MA, Schumacher HR, Espinoza LR et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res. 2010; 12:R63.
39. Schumacher HR, Becker MA, Lloyd E et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy study. Rheumatology. 2009; 48:188-94.
40. ClinicalTrials.gov. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities (CARES). www.clinicaltrials.gov/ct2/show/NCT01101035 (accessed 2010 Nov 23).
41. Becker MA, MacDonald PA, Hunt BJ. Determinants of the clinical outcomes of gout during the first year of uratelowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008; 27:585-91. (Pubitemid 351948555)
42. Red book 2010. 114th ed. Montvale, NJ: Thompson Reuters (Healthcare). 2010:191,686,794.